Fabry Disease Treatment Market Size & Share 2026-2035

Fabry Disease Treatment Market Size

The global fabry disease treatment market was valued at USD 2.5 billion in 2025. The market is expected to grow from USD 2.7 billion in 2026 to USD 5.6 billion in 2035, at a CAGR of 8.5% during the forecast period, according to the latest report published by Global Market Insights Inc.

The growing demand for highly effective, precise, and targeted therapies for Fabry disease is expected to significantly support market growth. Increasing prevalence of Fabry disease and its associated complications are driving the need for advanced treatment approaches worldwide. According to reports published by Fabry Disease News in May 2024, late-onset Fabry disease is relatively common, affecting approximately 1 in 1,000 to 3,000 males and 1 in 6,000 to 40,000 females. In contrast, the classic form of Fabry disease remains rare and is estimated to affect approximately 1 in 22,000 to 40,000 males.

The increasing prevalence of Fabry disease, combined with growing investments by pharmaceutical companies in the development of advanced and more effective treatment options, is accelerating the introduction of novel therapies and expanding treatment accessibility globally. These developments are expected to drive market expansion during the forecast period.

Fabry disease is a rare inherited genetic disorder that affects multiple organs, including the kidneys, heart, nervous system, skin, and eyes. Common symptoms include severe pain in the hands and feet (acroparesthesias), small dark-red skin lesions known as angiokeratomas, reduced sweating (hypohidrosis), and corneal abnormalities such as corneal opacity or corneal verticillata. The disease is caused by the accumulation of globotriaosylceramide (GL-3) within body tissues due to deficiency of the alpha-galactosidase A enzyme. Currently, enzyme replacement therapy (ERT) and chaperone therapy represent the most widely adopted and effective treatment approaches for Fabry disease management.

Key companies operating in the fabry disease treatment market include Sanofi, Takeda Pharmaceutical Company, and Amicus Therapeutics. These companies are actively advancing the market through expansion of enzyme replacement therapies, development of oral chaperone therapies, and ongoing research in next-generation gene therapy platforms. Strategic collaborations, clinical development programs, and regulatory approval initiatives are further supporting innovation and commercialization activities across major markets.

Between 2022 and 2024, the fabry disease treatment market witnessed steady growth, supported by improving diagnosis rates, increasing life expectancy among patients, and rising awareness regarding rare genetic disorders. During this period, the global market expanded from approximately USD 2.0 billion in 2022 to nearly USD 2.3 billion in 2024.

In addition, growing awareness initiatives by governments and nonprofit organizations, including Rare Diseases International, are contributing to improved disease recognition, patient support, and access to treatment. These initiatives are expected to positively influence demand for Fabry disease therapies and support long-term market growth.
 

Fabry Disease Treatment Market Trends

• Increasing government support, favorable regulatory policies, and rising funding for rare disease research are significantly contributing to the growth of the fabry disease treatment market.
• Government-backed initiatives are encouraging research and development activities focused on rare genetic disorders such as Fabry disease. For instance, the Canadian Minister of Health announced implementation of a National Strategy for Drugs for Rare Diseases with funding support of up to USD 1.5 billion over three years to improve access to innovative therapies and accelerate rare disease treatment development.
• Ongoing advancements in treatment modalities, including next-generation therapies such as venglustat (ibiglustat) and gene therapy like ST-920, are expected to support market expansion during the forecast period.
• In addition, leading market participants are continuously investing in clinical research and development activities aimed at introducing novel and more effective Fabry disease therapies. These investments are accelerating innovation and improving the availability of advanced treatment options.
• For example, Protalix BioTherapeutics secured approximately USD 43.7 million in financing to further advance its fabry disease treatment pipeline, highlighting growing investor confidence in innovative rare disease therapeutics.
• Regulatory agencies such as the U.S. Food and Drug Administration, the European Medicines Agency, and Japan’s Pharmaceuticals and Medical Devices Agency are also supporting market growth through orphan drug designations and accelerated development pathways for Fabry disease therapies. For instance, Exegenesis Bio received orphan drug designation from the U.S. FDA in December 2024 for its Fabry disease gene therapy candidate EXG110.
• Furthermore, increasing awareness and recognition of Fabry disease among healthcare professionals and patients, combined with the growing availability of advanced treatment options, are expected to further increase demand for Fabry disease therapies globally.

Fabry Disease Treatment Market Analysis

Based on treatment, the global fabry disease treatment market is divided into enzyme replacement therapy (ERT), chaperone treatment, and other treatment types. The enzyme replacement therapy (ERT) segment dominated the market and was valued at USD 1.9 billion in 2025.

• Growth of the ERT segment is primarily driven by the increasing prevalence and diagnosis rate of Fabry disease, as enzyme replacement therapy remains the standard treatment approach for replacing the deficient alpha-galactosidase A enzyme in affected patients.
• Advancements in diagnostic technologies, including next-generation sequencing and enzyme activity assays, have enabled earlier and more accurate diagnosis of Fabry disease, thereby increasing the number of patients eligible for ERT treatment. For example, Centogene expanded its collaboration with Takeda Pharmaceutical Company to continue providing diagnostic services for lysosomal storage disorders, supporting improved diagnosis and identification of Fabry disease patients.
• In addition, wider availability of ERT drugs through hospital pharmacies and specialty healthcare centers, along with regulatory approvals for advanced formulations such as Pegunigalsidase alfa (PRX-102), has expanded treatment accessibility. These newer formulations offer improved efficacy profiles and reduced infusion-related adverse reactions, further supporting segment growth.
• Meanwhile, the chaperone therapy segment is witnessing steady growth due to increasing adoption of oral precision-medicine therapies, expanding availability of mutation-specific treatment options, and rising awareness regarding amenable GLA gene variants among clinicians and patients.

Based on the route of administration, the global fabry disease treatment market is categorized into intravenous and oral. The intravenous segment dominated the market in 2025 and is anticipated to reach USD 3.8 billion by 2035 with a significant CAGR of 8.4% during the analysis period.

• Increasing diagnosis rates of Fabry disease, supported by improved awareness and expansion of genetic screening programs, are contributing to higher demand for intravenous therapies, particularly intravenous enzyme replacement treatments.
• Clinical studies have consistently demonstrated the long-term effectiveness of intravenous ERT in stabilizing disease progression and improving patient outcomes. For instance, a multicenter clinical trial conducted in 2021 reported that patients treated with Fabrazyme showed significant reductions in cardiac complications and improvements in kidney function over a five-year period.
• Furthermore, the presence of advanced healthcare infrastructure and specialized infusion facilities in developed regions such as North America and Europe continues to support adoption of intravenous Fabry disease therapies. These regions account for a significant proportion of patients receiving ERT-based treatment.
• In contrast, the oral segment is gaining traction due to growing adoption of Galafold, the first approved oral chaperone therapy for Fabry disease. The therapy offers greater convenience, improved patient adherence, and mutation-specific treatment benefits for eligible patients.  

Based on the end use, the global fabry disease treatment market is categorized into hospitals, homecare settings and other end users. The hospitals segment accounted for the highest market share of 58.1% in 2025.

• Hospitals remain the primary treatment setting for Fabry disease management due to the availability of advanced diagnostic technologies such as genetic testing and enzyme activity assays, which are essential for accurate disease identification and monitoring.
• In addition, hospitals serve as the major providers of enzyme replacement therapy, as ERT administration requires specialized infusion procedures and continuous patient monitoring, particularly during long-term treatment.
• Hospitals are also increasingly participating in clinical research collaborations and clinical trials focused on the development of novel Fabry disease therapies. The establishment of specialized rare disease treatment centers and increasing availability of dedicated Fabry disease care programs are further contributing to market growth.
• Meanwhile, the homecare settings segment is projected to witness the fastest growth during the forecast period, supported by increasing adoption of home-based intravenous infusion services and growing patient preference for convenient, lower-burden treatment administration outside traditional hospital settings.

North America Fabry Disease Treatment Market

The North America dominated the global fabry disease treatment market with a share of 44.8% in 2025.

• The region maintains its leading position due to early adoption of advanced Fabry disease therapies, strong presence of major biopharmaceutical companies, and a well-established rare disease treatment ecosystem that supports rapid diagnosis, treatment accessibility, and clinical adoption.

• In addition, the presence of key market participants such as Sanofi, and Amicus Therapeutics continues to strengthen regional market growth through ongoing development, commercialization, and expansion of innovative Fabry disease therapies.

The U.S. fabry disease treatment market was valued at USD 818.1 million and USD 879.1 million in 2022 and 2023, respectively. The market size reached USD 1 billion in 2025, growing from USD 945.8 million in 2024.

• Market growth in the U.S. is supported by favorable government initiatives, increasing awareness regarding rare genetic disorders, rising diagnosis rates, and expanding availability of advanced treatment options for Fabry disease.
• According to the National Fabry Disease Foundation, approximately 50,000 individuals in the U.S. are living with Fabry disease, including both classic and late-onset forms of the disorder.
• Awareness initiatives undertaken by healthcare organizations and pharmaceutical companies are also contributing to improved diagnosis and treatment adoption. For instance, in May 2024, the American Kidney Fund collaborated with Sanofi to launch an awareness campaign encouraging chronic kidney disease (CKD) patients with unknown underlying causes to undergo Fabry disease testing. Thus, increasing awareness initiatives and screening programs are expected to support earlier diagnosis and timely treatment initiation, thereby contributing to the market growth.

Europe Fabry Disease Treatment Market

Europe market accounted for USD 709.6 million in 2025 and is anticipated to show lucrative growth over the forecast period.

• Market growth in Europe is supported by increasing adoption of advanced treatment approaches, including enzyme replacement therapies (ERTs) and chaperone therapies, along with growing clinical research focused on next-generation gene therapies for Fabry disease management.
• In addition, regulatory approvals for novel therapies are expanding treatment accessibility across the region. For example, Amicus Therapeutics received approval from the European Commission for the use of Galafold in adolescents aged 12 to below 16 years weighing at least 45 kg with confirmed Fabry disease, supporting broader commercialization opportunities in Europe..

Germany shows strong growth potential in the Europe fabry disease treatment market.

• Germany benefits from one of the most advanced healthcare systems in Europe, enabling improved access to early diagnosis, specialized rare disease treatment centers, and advanced therapeutic options for Fabry disease patients.
• The country is also recognized as a major research hub for rare disease studies, supported by organizations such as the German Center for Rare Diseases. Ongoing clinical trials and research activities focused on gene therapies and precision medicine approaches are attracting substantial investments in the country.

Asia Pacific Fabry Disease Treatment Market

The Asia Pacific market is anticipated to grow at the highest CAGR of 8.8% during the analysis timeframe.

• Regional growth is driven by rapid improvements in healthcare infrastructure, increasing access to enzyme replacement and chaperone therapies, and strengthening government support for rare disease management across countries such as Japan, China, and South Korea.
• In addition, expansion of advanced diagnostic capabilities, including genetic testing initiatives and improved specialist referral networks, is supporting earlier identification of Fabry disease patients and timely treatment initiation across the region.

China fabry disease treatment market is expected to grow significantly in Asia Pacific region during the analysis period.

• Market growth in China is supported by continuous improvements in healthcare infrastructure and increasing accessibility to advanced rare disease therapies, particularly in major urban healthcare centers.
• The country has also witnessed approvals and broader availability of enzyme replacement therapies and oral chaperone therapies for Fabry disease, improving treatment accessibility for patients.
• Furthermore, government initiatives focused on rare disease management, including inclusion of select rare disease therapies within national reimbursement and insurance programs, are improving affordability and supporting market expansion in China.

Latin American Fabry Disease Treatment Market

Brazil leads the Latin American fabry disease treatment industry, exhibiting remarkable growth during the analysis period.

• The Brazilian government has implemented policies aimed at improving access to treatment for rare diseases through the National Policy for Comprehensive Care for People with Rare Diseases, under which Fabry disease is recognized as a condition requiring specialized care and long-term management.
• In addition, pharmaceutical companies are increasingly expanding their presence in Brazil through commercialization of leading Fabry disease therapies such as Fabrazyme (agalsidase beta) and Replagal (agalsidase alfa).
• Patient advocacy and awareness initiatives led by organizations such as the Brazilian Fabry Disease Association are also supporting improved disease awareness, patient support, and treatment accessibility across the country.

Middle East and Africa Fabry Disease Treatment Market

Saudi Arabia is anticipated to grow in the Middle East and Africa fabry disease treatment industry.

• Market expansion in the country is supported by significant investments in healthcare infrastructure under the Saudi Vision 2030 initiative, which aims to strengthen healthcare services and improve management of rare genetic disorders.
• Increasing emphasis on genetic screening and early diagnosis programs is also contributing to improved identification and treatment of Fabry disease patients in Saudi Arabia.
• In addition, the country’s universal healthcare system provides substantial financial support for treatment of rare diseases, including Fabry disease, reducing patient cost burden and improving access to high-cost therapies such as enzyme replacement treatment.

Fabry Disease Treatment Market Share

The top 5 players such as Sanofi, Takeda Pharmaceutical, BioMarin Pharmaceutical (Amicus Therapeutics), Protalix BioTherapeutics and JCR Pharmaceuticals accounts for approximately 65% of the market share in 2025. These players focus on various strategies such as acquisition, business expansion, research and development activities and novel product launches to consolidate their market presence. For instance, in February 2022, Takeda Pharmaceutical Company and Sumitomo Dainippon Pharma, announced that Takeda succeed the manufacturing and marketing approval and the marketing rights of REPLAGAL 3.5 mg for Fabry disease, an α-galactosidase enzyme intravenous (IV) infusion from Sumitomo Dainippon Pharma.

Established pharmaceutical giants offer a well-known fabry disease treatment under various brand names. Key players are engaging in strategic initiatives such as collaboration, product launch, investment, and partnerships to strengthen their product portfolio. The companies are actively adopting a multi-pronged approaches to address the rising demand for fabry disease treatment. Furthermore, the market is highly consolidated with few players operating in the market. Hence, leading players are constantly adopting key strategies for the growth of the market.

Strategic expansion through clinical partnerships, accelerated approval pathways, and advanced biologics manufacturing investments continues to shape the evolving competitive landscape. For instance, accelerated FDA pathways in North America such as the fast‑tracked development of Sangamo’s ST‑920 gene therapy are reshaping innovation timelines and intensifying competition among pipeline developers. Meanwhile, Protalix and Chiesi have strengthened their market position with the global rollout of Elfabrio following regulatory approvals in the U.S. and Europe, supported by efforts to expand long‑term infusion‑based delivery options.

Fabry Disease Treatment Market Companies

Prominent players operating in the fabry disease treatment industry are as mentioned below:

• Avrobio
• BioMarin Pharmaceutical (Amicus Therapeutics)
• Freeline Therapeutics
• Idorsia Pharmaceuticals
• ISU Abxis
• JCR Pharmaceuticals
• Novartis
• Pfizer
• Protalix BioTherapeutics
• Sanofi SA
• Takeda Pharmaceuticals
• Viatris

• Sanofi

Sanofi holds the leading position in the global fabry disease treatment market, anchored by Fabrazyme, the most widely adopted enzyme replacement therapy (ERT) worldwide. The company’s strong market presence is reinforced by Fabrazyme’s long‑standing clinical use, broad regulatory approvals, and high uptake across the U.S., Europe, and other major regions. Sanofi continues to enhance its leadership through ongoing investment in rare‑disease R&D and global treatment accessibility, solidifying its role as the dominant provider of Fabry disease therapies.

• Takeda Pharmaceutical

Takeda maintains a strong competitive standing in the Fabry disease market through Replagal, a widely used ERT with deep clinical adoption across Europe and Japan. Its position is strengthened by decades of real‑world data, sustained demand in regions where Replagal remains a primary treatment option, and the company’s expanding rare‑disease expertise. Takeda continues to reinforce long‑term growth by advancing next‑generation therapeutics and leveraging its extensive global infrastructure across metabolic and genetic disorders.

• BioMarin Pharmaceutical (Amicus Therapeutics)

Amicus plays a pivotal and fast‑growing role in the Fabry treatment landscape, driven by Galafold, the first and only approved oral chaperone therapy. Its leadership in precision‑medicine treatment is supported by Galafold’s approval in more than 40 countries and its ability to serve patients with amenable GLA mutations. Amicus strong innovation‑driven strategy and continued investment in chaperone science and rare‑disease R&D position the company as a major force accelerating the shift toward targeted, patient‑centric Fabry therapies.

Fabry Disease Treatment Industry News

• In March 2026, Genomenon announced a collaboration with Amicus Therapeutics to advance Fabry disease awareness and genetic diagnosis. The effort expanded publicly available Fabry disease variant data for global clinical use. This enhanced Amicus’ support for improved diagnostic accuracy in Fabry disease.
• In December 2025, BioMarin agreed to acquire Amicus Therapeutics. The acquisition added Galafold for Fabry disease and Pombiliti with Opfolda for Pompe disease. This strengthened BioMarin’s rare‑disease portfolio and expanded its commercial reach.
• In November 2023, uniQure announced that the U.S. Food and Drug Administration (FDA) cleared the Investigational New Drug (IND) application for AMT-191, the Company’s gene therapy candidate for Fabry disease. AMT-191 comprises an AAV5 vector that delivers a -galactosidase A (GLA) transgene designed to target the liver and produce the deficient GLA protein. This helped the company expand its product range.
• In May 2023, Chiesi Global Rare Diseases, announced that the U.S. Food and Drug Administration (FDA) has approved PRX-102 (pegunigalsidase alfa-iwxj) in the U.S. for the treatment of adult patients with Fabry disease. This product approval helped the company expand its product range in U.S. market.
• In May 2023, Sangamo Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to isaralgagene civaparvovec, or ST-920, a wholly owned gene therapy product candidate for the treatment of Fabry disease. This approval aimed to broaden the treatment availability, complementing existing therapies for Fabry disease.

The fabry disease treatment market research report includes in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2022 – 2035 for the following segments:

Market, By Treatment

• Enzyme replacement therapy (ERT)
• Chaperone treatment
• Other treatment types

Market, By Route of Administration

• Intravenous
• Oral

Market, By End Use

• Hospitals
• Homecare settings
• Other end users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea

• Latin America
  • Brazil
  • Mexico
  • Argentina

• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE